On May 19, 2016 Stemline Therapeutics, Inc. (Nasdaq:STML) reported that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) was selected for oral presentations at both the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting being held in Chicago, IL and the 21st Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) being held in Copenhagen, Denmark. The full abstracts are now available on the respective conference websites (Press release, Stemline Therapeutics, MAY 19, 2016, View Source [SID:1234512589]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the ASCO (Free ASCO Whitepaper) presentation are as follows:
Title: Results from Phase 2 registration trial of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lead-in completed, Expansion stage ongoing
Presenter: Naveen Pemmaraju, M.D., MD Anderson Cancer Center
Abstract No.: 7006
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date/Time: Saturday, June 4, 2016; 5:00 – 5:12PM CT
Location: Arie Crown Theater
Details on the EHA (Free EHA Whitepaper) presentation are as follows:
Title: Results from ongoing Phase 2 registration study of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Presenter: Naveen Pemmaraju, M.D., MD Anderson Cancer Center
Abstract No.: S812
Session: Treatment in Specific AML Subgroups
Date/Time: Sunday, June 12, 2016; 9:00 – 9:15 AM CET
Location: Hall C13
Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, commented, "We are honored that our trial results have been selected for oral presentation by both ASCO (Free ASCO Whitepaper) and the EHA (Free EHA Whitepaper). We believe this selection underscores the exciting clinical data we have witnessed with SL-401, and highlights the increased awareness of BPDCN, a devastating malignancy of high unmet medical need, across both the U.S. and Europe."
Dr. Bergstein continued, "We remain very encouraged by SL-401’s continued strong performance to date. And we plan to provide updated enrollment, response rates and duration, as well as preliminary progression-free and overall survival data from the trial at the upcoming conferences."
Dr. Bergstein concluded, "We look forward to continuing to advance SL-401 in an effort to provide patients this promising agent as rapidly as possible. Over the remainder of the year, we also plan to provide further clinical and regulatory updates from this study as well as our other clinical programs spanning multiple indications."